… subclinical atherosclerosis to primary prevention and moderate-intensity statin therapy; high-…
not consider subclinical atherosclerosis as an indication for nonstatin therapies. The same …

… lipid-lowering treatment in primary and secondary prevention patients seen … treatment
guidelines and their intensity at the time of inclusion in the registry, as well as changes in treatment …

… CA atherosclerosis development, by which dyslipidemia induces… and non-drug therapies for
atherosclerotic CA stenosis. … to support the secondary stroke prevention associated with post-…

… role in the development of atherosclerosis, and clarifying the … for dyslipidemias, the potential
value of measuring secondary … and emergent treatment options, and their potential role in …

… Dyslipidemia is a risk factor for atherosclerotic cardiovascular disease (ASCVD). Abundant
… as well as in addition to statin therapy. Second, they are optimally dosed subcutaneously …

… and their physicians. Additionally, it is increasingly understood that atherosclerotic burden
… risk-based clinical categories, such as primary or secondary prevention, not only fall short in …

… Non-HDL cholesterol is well defined as a secondary target in the treatment of
dyslipidemias in the European Atherosclerosis Society/European Society of Cardiology (EAS/ESC) …

… (T2DM) is associated with increased risk for atherosclerotic … related to atherogenic dyslipidemia
with raised triglycerides, … Statin treatment is recommended for primary and secondary …

… Cholesterol-lowering medications have been used to provide both primary and secondary
… and LDL-C is associated with the development of atherosclerotic heart diseases (ASCVD) …

… therapy still have significant remaining CV risk. Therefore, managing the unresolved residual
risk is the ultimate purpose of treating atherosclerosis … A prespecified secondary analysis of …